We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | NASDAQ:RIGL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.1801 | -15.13% | 1.0099 | 1.00 | 1.01 | 1.125 | 0.98 | 1.11 | 3,544,867 | 00:33:36 |
From May 2019 to May 2024
By Colin Kellaher
Eli Lilly & Co. on Thursday said it would receive an exclusive worldwide license to Rigel Pharmaceuticals Inc.'s receptor-interacting serine/threonine-protein kinase 1, or RIPK1, inhibitors as part of a collaboration with the clinical-stage biotechnology company.
Eli Lilly said it would make an up-front payment of $125 million to Rigel, which would also be eligible for up to $835 million in future development, regulatory and commercial milestones, along with royalties on sales.
The Indianapolis drugmaker said the companies plan to co-develop and commercialize Rigel's Phase 2-ready R552 inhibitor for all indications, including autoimmune and inflammatory diseases.
Eli Lilly said it would also lead all clinical development of brain-penetrating RIPK1 inhibitors in central-nervous-system diseases.
Shares of South San Francisco, Calif.-based Rigel, which closed Wednesday at $4.53, jumped more than 40% in premarket trading Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2021 07:09 ET (12:09 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Rigel Pharmaceuticals Chart |
1 Month Rigel Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
